Astagraf XL FDA Approval History
FDA Approved: Yes (First approved July 19, 2013)
Brand name: Astagraf XL
Generic name: tacrolimus
Dosage form: Extended-Release Capsules
Company: Astellas Pharma US, Inc.
Treatment for: Organ Transplant, Rejection Prophylaxis
Astagraf XL (tacrolimus) is a calcineurin-inhibitor immunosuppressant for the prophylaxis of organ rejection in patients receiving a kidney transplant.
Development Timeline for Astagraf XL
|Jul 22, 2013||Astellas Announces FDA Approval of Astagraf XL (tacrolimus extended-release capsules) for the Prophylaxis of Organ Rejection|
|Dec 26, 2005||NDA for Immunosuppressant FK506 Modified Release Formulation Submitted in the US|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.